• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Opinion
Video

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

Video content above is prompted by the following questions:

  • What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
    • Discuss the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib.
Related Videos
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
4 KOLs are featured in this series
4 KOLs are featured in this series
Mabel Mardones, MD.
Mei Wei, MD.
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.